Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2002 Nov-Dec;49(48):1487-90.

Comparing combined hepatocellular-cholangiocarcinoma and cholangiocarcinoma: a clinicopathological study

Affiliations
  • PMID: 12397714
Comparative Study

Comparing combined hepatocellular-cholangiocarcinoma and cholangiocarcinoma: a clinicopathological study

Cheng-Chi Lee et al. Hepatogastroenterology. 2002 Nov-Dec.

Abstract

Background/aims: Combined hepatocellular-cholangiocarcinoma is a rare subtype of primary liver cancer. To clarify the significance of this tumor, we conducted the present study to investigate the clinicopathological characteristics. As well, a comparison between this tumor and cholangiocarcinoma was made to determine whether these two types of liver cancers are closely related.

Methodology: Seventeen cases of combined hepatocellular-cholangiocarcinoma and 104 cases of cholangiocarcinoma were included. Patients were evaluated on the basis of age, gender, viral hepatitis markers, tumor markers, laboratory data, indocyanine green test, tumor location, histological differentiation, lymph node involvement, and organ metastasis. In addition, the presenting symptoms at admission were also recorded. Data was analyzed using the chi 2 test and Student's t test and differences between the curves were tested using the two-tailed log-rank test.

Results: Combined hepatocellular-cholangiocarcinoma was found to be more prevalent in males. In addition, the combined hepatocellular-cholangiocarcinoma patients had lower serum bilirubin, ALP levels (p < 0.05), and more poor differentiation (p < 0.05). Also, the presenting symptoms of combined hepatocellular-cholangiocarcinoma patients were different from those of cholangiocarcinoma patients with the former a lower incidence of fever, chills, jaundice and a higher incidence of fatigue and weakness.

Conclusions: The clinicopathological features of combined hepatocellular-cholangiocarcinoma were different from those of cholangiocarcinoma with more advanced histological differentiation, more prevalent in males, and lower levels of serum bilirubin and ALP. These characteristic features may help us in diagnosing combined hepatocellular-cholangiocarcinoma in patients with suspected cholangiocarcinoma.

PubMed Disclaimer

Publication types

LinkOut - more resources